| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.13.4.359 |
| P698 | PubMed publication ID | 15102586 |
| P2093 | author name string | Athanasios G Papavassiliou | |
| Michalis V Karamouzis | |||
| P2860 | cites work | Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? | Q24536027 |
| Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro | Q24799983 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention | Q28193249 | ||
| Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. | Q53391057 | ||
| Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. | Q53961800 | ||
| A randomized trial of aspirin to prevent colorectal adenomas | Q28195296 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2 | Q28573372 | ||
| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis | Q29616121 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Carcinogen substrate specificity of human COX-1 and COX-2. | Q31835278 | ||
| Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study | Q33348167 | ||
| Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis | Q33834295 | ||
| Rofecoxib reduces polyp recurrence in familial polyposis | Q33974041 | ||
| The coxibs, selective inhibitors of cyclooxygenase-2. | Q34086325 | ||
| Redefining the target: chemotherapeutics as antiangiogenics | Q34142103 | ||
| Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis | Q34156486 | ||
| Many actions of cyclooxygenase-2 in cellular dynamics and in cancer | Q34539982 | ||
| COX-2 inhibitors in cancer treatment and prevention, a recent development | Q34568813 | ||
| The role of cyclooxygenase inhibitors in cancer prevention | Q34595366 | ||
| A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis | Q34637596 | ||
| Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. | Q34680750 | ||
| Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention | Q34796087 | ||
| Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer | Q34804039 | ||
| Current concepts in cyclooxygenase inhibition in breast cancer | Q34969789 | ||
| Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention | Q35011895 | ||
| Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy | Q35033434 | ||
| Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment | Q35043366 | ||
| Cyclooxygenase 2: a molecular target for cancer prevention and treatment | Q35057356 | ||
| Prostate cancer: horizons in the development of novel anti-cancer strategies | Q35100605 | ||
| Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review | Q35138602 | ||
| Valdecoxib: a review | Q35174224 | ||
| COX-2 selective inhibitors: analysis of the renal effects | Q35194538 | ||
| Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? | Q35196709 | ||
| Cyclo-oxygenase 2 inhibition in colorectal cancer therapy | Q35208078 | ||
| Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. | Q35595971 | ||
| Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways | Q40880153 | ||
| The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity | Q44300952 | ||
| Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation | Q44327392 | ||
| Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma | Q44392696 | ||
| Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer | Q44513206 | ||
| Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition | Q44582774 | ||
| Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report | Q44659442 | ||
| Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. | Q53376153 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 359-372 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? | |
| P478 | volume | 13 |
| Q91974677 | COX-2 as a potential biomarker and therapeutic target in melanoma |
| Q40233446 | Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study. |
| Q36764481 | Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis |
| Q39640869 | Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production |
| Q34234484 | The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro |
| Q57703131 | Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives |
| Q90542917 | siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease |
| Q94076162 | siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease |
Search more.